In addition to our primary findings, we determined that gp100, a marker used routinely for identification of CTCs [7] in uveal melanoma and the target for the recently FDA-approved tebentafusp for metastatic disease [4], was insufficient for identification of disseminated cancer cells in primary uveal melanoma patients with more aggressive disease. Here, PMEL is linked to metastatic neoplasm.